EU Approves Pfizer-BioNTech XFG-Targeting COVID-19 Vaccine for 2026-2027 Season

Geographically, the marketing authorization is valid across all 27 EU Member States, as well as Iceland, Liechtenstein, and Norway .

Regulatory Process

The approval followed a structured regulatory pathway. On May 29, 2026, the EMA's Emergency Task Force (ETF) recommended updating COVID-19 vaccines to target XFG for the 2026/2027 vaccination campaign. The ETF noted that XFG had been circulating widely since at least summer 2025 . Within the JN.1 family, the ETF stated that XFG was the preferred choice, while noting that other JN.1 descendants like LP.8.1 could also be considered .

The EMA's Committee for Medicinal Products for Human Use (CHMP) subsequently assessed the adaptation and issued a positive recommendation in July 2026 . The European Commission then granted the centralized marketing authorization on July 29, 2026 . This variant-adaptation approval follows an accelerated pathway similar to previous strain updates for Comirnaty.

Immune Response Data

Pfizer and BioNTech report that data indicate the XFG-adapted formula induces a strong immune response against contemporary circulating and emerging lineages of SARS-CoV-2 . Additionally, the EMA ETF stated that XFG vaccines are expected to provide protection against BA.3.2 .

No specific numeric immunogenicity titers or neutralization fold-rises have been publicly released in the press announcements .

Supply Readiness & Distribution

Shipping will begin soon to ensure rapid access across EU member states ahead of the autumn/winter respiratory season . The authorization allows the companies to proceed with manufacturing and supply chain execution .

Pfizer and BioNTech note that over 5 billion doses of their COVID-19 vaccines have been supplied globally to date .

Global Context

The EU authorization aligns with a broader seasonal rhythm: annual updates to COVID-19 vaccines similar to influenza strain selection . Globally, mRNA COVID-19 vaccines have transitioned to an annual seasonal update model, with regulators coordinating variant strain selection and manufacturers adapting formulations each year.

Known Safety Risks

The XFG-adapted vaccine is an mRNA vaccine based on the same Comirnaty platform, so its safety profile is expected to be consistent with prior Comirnaty formulations . For the Comirnaty class, the established and monitored risks include:

• Myocarditis and pericarditis: Increased risk observed in postmarketing data, particularly in younger males .
• Anaphylaxis / severe allergic reactions: Rare cases reported; vaccines must be given under close medical supervision with appropriate treatment available .
• Common adverse reactions: Injection site pain, fatigue, headache, muscle pain (up to 18.1%), chills (up to 13.3%), fever (up to 7.8%), and joint pain (up to 7.6%) — generally mild to moderate and short-lived (1-2 days) .
• Other pre-specified adverse events of special interest (AESIs) in ongoing protocols include Guillain-Barré syndrome, Bell's palsy, convulsions/seizures, cerebral venous sinus thrombosis, and encephalitis/myelitis .

The companies and EMA continue routine pharmacovigilance and periodic safety update reporting for all adapted formulations .